Shelby Derene Reed, PhD

Professor in Population Health Sciences
Professor in Medicine
Associate of the Duke Initiative for Science & Society
Member in the Duke Clinical Research Institute
Member of the Duke Cancer Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8991
Email address shelby.reed@duke.edu

Shelby Reed, PhD, RPh is Professor in Population Health Sciences and Medicine at Duke University and Director of the Preference Evaluation Research (PrefER) Group at the Duke Clinical Research Institute.  She also is core faculty and serves on the executive committee at the Duke-Margolis Center for Health Policy. Dr. Reed has 20 years of experience leading multidisciplinary health outcomes research studies. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of diagnostics, drugs and patient-centered interventions. In evaluating health policy issues, she has developed computer models to evaluate the economic impact of trends in clinical trial design, changes in reimbursement policies, a new financing scheme to spur drug development for ultra-rare conditions, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.  Dr. Reed earned pharmacy and doctoral degrees from the University of Maryland and completed her training in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. She serves on editorial advisory boards for Value in Health and Health Services Research.  She served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 2017-2018.

Shelby Reed, PhD, RPh is Professor in Population Health Sciences and Medicine at Duke University and Director of the Preference Evaluation Research (PrefER) Group at the Duke Clinical Research Institute.  She also is core faculty and serves on the executive committee at the Duke-Margolis Center for Health Policy. Dr. Reed has 20 years of experience leading multidisciplinary health outcomes research studies. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of diagnostics, drugs and patient-centered interventions. In evaluating health policy issues, she has developed computer models to evaluate the economic impact of trends in clinical trial design, changes in reimbursement policies, a new financing scheme to spur drug development for ultra-rare conditions, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.  Dr. Reed earned pharmacy and doctoral degrees from the University of Maryland and completed her training in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. She serves on editorial advisory boards for Value in Health and Health Services Research.  She served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in 2017-2018. she is currently Chair of ISPOR's Health Science Policy Council.

 

Areas of expertise: Health Economics, Health Measurement, Stated Preference Research, Health Policy, and Health Services Research

Education and Training

  • Ph.D., University of Maryland, College Park, 1998

Publications

Bewtra, Meenakshi, Shelby D. Reed, F Reed Johnson, Frank I. Scott, Erin Gilroy, Robert S. Sandler, Wenli Chen, and James D. Lewis. “Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents..” Clin Gastroenterol Hepatol 18, no. 2 (February 2020): 406-414.e7. https://doi.org/10.1016/j.cgh.2019.05.010.

PMID
31100456
Full Text

Havrilesky, Laura J., Jui-Chen Yang, Paula S. Lee, Angeles Alvarez Secord, Jessie A. Ehrisman, Brittany Davidson, Andrew Berchuck, Kathleen M. Darcy, G Larry Maxwell, and Shelby D. Reed. “Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer..” Cancer 125, no. 24 (December 15, 2019): 4399–4406. https://doi.org/10.1002/cncr.32447.

PMID
31454432
Full Text

Reed, Shelby D., Yanhong Li, Helen A. Dakin, Frauke Becker, Jose Leal, Stephanie M. Gustavson, Bernt Kartman, et al. “Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)..” Diabetes Care, December 5, 2019. https://doi.org/10.2337/dc19-0950.

PMID
31806653
Full Text

Reed, Shelby D., Angelyn O. Fairchild, F Reed Johnson, Juan Marcos Gonzalez, Robert J. Mentz, Mitchell W. Krucoff, and Sreekanth Vemulapalli. “Patients' Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms..” Circ Cardiovasc Interv 12, no. 12 (December 2019). https://doi.org/10.1161/CIRCINTERVENTIONS.119.008051.

PMID
31752516
Full Text

Saullo, Jennifer L., Yanhong Li, Julia A. Messina, Jillian Thompson, Tara Dalton, Vinay K. Giri, Shelby D. Reed, et al. “Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy..” Biol Blood Marrow Transplant, November 9, 2019. https://doi.org/10.1016/j.bbmt.2019.11.005.

PMID
31712193
Full Text

Hung, A., Y. Li, F. J. Keefe, D. C. Ang, J. Slover, R. A. Perera, L. Dumenci, S. D. Reed, and D. L. Riddle. “Ninety-day and one-year healthcare utilization and costs after knee arthroplasty..” Osteoarthritis Cartilage 27, no. 10 (October 2019): 1462–69. https://doi.org/10.1016/j.joca.2019.05.019.

PMID
31176805
Full Text

Johnson, F Reed, Rachael L. DiSantostefano, Jui-Chen Yang, Shelby D. Reed, Johannes Streffer, and Bennett Levitan. “Something Is Better Than Nothing: The Value of Active Intervention in Stated Preferences for Treatments to Delay Onset of Alzheimer's Disease Symptoms..” Value Health 22, no. 9 (September 2019): 1063–69. https://doi.org/10.1016/j.jval.2019.03.022.

PMID
31511183
Full Text

Levitan, B. S., E. G. Katz, R. L. DiSantostefano, J. C. Yang, A. O. Fairchild, S. D. Reed, and F. R. Johnson. “Beating the Benchmarks: Using Patient Preferences to Increase the Probability of Development Success.” In Patient Patient Centered Outcomes Research, 12:431–431. ADIS INT LTD, 2019.

Scholars@Duke

Reed, Shelby D., Angelyn O. Fairchild, F. R. Johnson, Juan M. Gonzalez, Robert J. Mentz, Mitchell W. Krucoff, and Sreekanth Vemulapalli. “Patients Accept Mortality Risk for Improvements in Physical Functioning in Secondary Mitral Regurgitation.” In Journal of Cardiac Failure, 25:S149–S149. Elsevier BV, 2019. https://doi.org/10.1016/j.cardfail.2019.07.430.

Full Text

Pages